Forecast: This Healthcare Stock May Rise by 40% by 2026

Novo Nordisk Faces Challenges and New Opportunities

Novo Nordisk encountered significant difficulties in 2025, which ultimately resulted in the departure of its CEO.

However, the introduction of Wegovy’s new oral pill might be a turning point for the company.

This development could positively impact stocks that have appealing valuations.

Novo Nordisk, traded under the ticker (NYSE:NVO), was instrumental in transforming the obesity drug market, thanks to the remarkable success of its GLP-1 agonist drugs, Ozempic for type 2 diabetes and Wegovy for weight management. Yet, increased competition from other companies, including Eli Lilly, led to challenging times for Novo Nordisk. The situation deteriorated to the point where the CEO was effectively let go last May. Since reaching its peak in mid-2024, the stock has plummeted, losing over half its value.

Despite recent turmoil, Novo Nordisk’s shares have shown some recovery, with forecasts suggesting a possible 40% rise this year.

The company made headlines in early January with the FDA approval of Wegovy’s oral tablet. Previously administered through injections, the new pill offers a more user-friendly option for patients who are averse to needles.

The new leadership has played an active role in promoting the pill, alongside a well-established supply network that includes Amazon and Costco, making it widely accessible. In just the first week after launch, around 3,100 prescriptions were filled, escalating to about 8,000 by the second week.

As Wegovy is currently the only oral weight management pill available, Novo Nordisk can expect substantial revenue growth as the pill gains traction. Early reports of its success have already lifted the stock price from recent lows.

So, what’s the outlook for investors? Historically, Novo Nordisk has maintained an average price-to-earnings (P/E) ratio of around 27 over the last decade. Interestingly, it’s currently trading at a lower P/E of 18. If confidence in the company rebounds, it might move closer to its historic valuation.

If we take a conservative stance and apply a P/E ratio of 25, analysts predict that Novo Nordisk will earn approximately $3.49 per share this year. This valuation suggests a potential stock price of $87.25, indicating a 40% increase from the current price.

Of course, Novo Nordisk will need to capitalize on the successful launch of Wegovy Pills and capture market share before facing inevitable competition. Still, the company has a relatively straightforward path to generating substantial results for investors in the coming years.